ARTICLE | Clinical News
Dovitinib lactate: Phase II data
June 13, 2011 7:00 AM UTC
An open-label, international Phase II trial in 20 evaluable patients with hormone receptor-positive/FGFR1+ metastatic breast cancer showed that once-daily 500 mg dovitinib produced 3 unconfirmed parti...